Modeling cognitive dysfunction in neurofibromatosis-1

Trends in Neurosciences

Volumn 36, Issue 4, 2013, Pages 237-247

  Diggs Andrews, Kelly A ^a   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Attention deficits; Cyclic AMP; Dopamine; Learning; Neurofibromin; NF1

Indexed keywords

CYCLIC AMP; DOPAMINE; METHYLPHENIDATE; MEVINOLIN; NEUROFIBROMIN; RAS PROTEIN;

ATTENTION; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CLINICAL FEATURE; COGNITIVE DEFECT; HOMEOSTASIS; HUMAN; LEARNING; MEMORY; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; COGNITION DISORDERS; CYCLIC AMP; DISEASE MODELS, ANIMAL; HUMANS; NEUROFIBROMATOSIS 1; SIGNAL TRANSDUCTION;

EID: 84875829967     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2012.12.002     Document Type: Review

References (115)

1. Hyman S.L., et al. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005, 65:1037-1044.
2. Mautner V.F., et al. Treatment of ADHD in neurofibromatosis type 1. Dev. Med. Child Neurol. 2002, 44:164-170.
3. Hyman S.L., et al. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev. Med. Child Neurol. 2006, 48:973-977.
4. Ferner R.E. The neurofibromatoses. Pract. Neurol. 2010, 10:82-93.
5. Wallace M.R., et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990, 249:181-186.
6. Tonsgard J.H. Clinical manifestations and management of neurofibromatosis type 1. Semin. Pediatr. Neurol. 2006, 13:2-7.
7. National Institutes of Health Consensus Development Conference Neurofibromatosis. Conference statement. Arch. Neurol. 1988, 45:575-578.
8. Sabol Z., et al. Clinical sensitivity and specificity of multiple T2-hyperintensities on brain magnetic resonance imaging in diagnosis of neurofibromatosis type 1 in children: diagnostic accuracy study. Croat. Med. J. 2011, 52:488-496.
9. Hyman S.L., et al. Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology 2003, 60:1139-1145.
10. Johnson B.A., et al. Motor proficiency in children with neurofibromatosis type 1. Pediatr. Phys. Ther. 2010, 22:344-348.
11. Soucy E.A., et al. Developmental delays in children with neurofibromatosis type 1. J. Child Neurol. 2012, 27:641-644.
12. Soucy E.A., et al. Height assessments in children with neurofibromatosis type 1. J. Child Neurol. 2012, 10.1177/0883073812446310.
13. Gutmann D.H., et al. Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 2002, 59:759-761.
14. North K.N., et al. Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 1997, 48:1121-1127.
15. Acosta M.T., et al. Neurofibromatosis type 1: new insights into neurocognitive issues. Curr. Neurol. Neurosci. Rep. 2006, 6:136-143.
16. Payne J.M., et al. Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials. J. Neurol. 2013, 260:214-220.
17. Acosta M.T., et al. The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am. J. Med. Genet. A 2012, 158A:2225-2232.
18. Johnson H., et al. Psychological disturbance and sleep disorders in children with neurofibromatosis type 1. Dev. Med. Child Neurol. 2005, 47:237-242.
19. Coude F.X., et al. Academic impairment is the most frequent complication of neurofibromatosis type-1 (NF1) in children. Behav. Genet. 2006, 36:660-664.
20. Descheemaeker M.J., et al. Behavioural, academic and neuropsychological profile of normally gifted Neurofibromatosis type 1 children. J. Intellect. Disabil. Res. 2005, 49:33-46.
21. Barton B., North K. Social skills of children with neurofibromatosis type 1. Dev. Med. Child Neurol. 2004, 46:553-563.
22. Maddrey A.M., et al. Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma. J. Neurooncol. 2005, 72:245-253.
23. Isenberg J.C., et al. Attention skills in children with neurofibromatosis type 1. J. Child Neurol. 2013, 28:45-49.
24. Viskochil D., et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990, 62:187-192.
25. Gutmann D.H., et al. Developmental regulation of a neuron-specific neurofibromatosis 1 isoform. Ann. Neurol. 1999, 46:777-782.
26. Geist R.T., Gutmann D.H. Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene. Neurosci. Lett. 1996, 211:85-88.
27. Gutmann D.H., et al. Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues. Dev. Dyn. 1995, 202:302-311.
28. Costa R.M., et al. Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat. Genet. 2001, 27:399-405.
29. Xu H., Gutmann D.H. Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain Res. 1997, 759:149-152.
30. Gutmann D.H., et al. Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues. Cell Growth Differ. 1995, 6:315-323.
31. Basu T.N., et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992, 356:713-715.
32. Bollag G., et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 1996, 12:144-148.
33. DeClue J.E., et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992, 69:265-273.
34. Lau N., et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J. Neuropathol. Exp. Neurol. 2000, 59:759-767.
35. The I., et al. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 1997, 276:791-794.
36. Guo H.F., et al. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science 1997, 276:795-798.
37. Tong J., et al. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat. Neurosci. 2002, 5:95-96.
38. Dasgupta B., et al. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J. Neurosci. 2003, 23:8949-8954.
39. Hannan F., et al. Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. Hum. Mol. Genet. 2006, 15:1087-1098.
40. Jacks T., et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet. 1994, 7:353-361.
41. Cichowski K., et al. Nf1 gene targeting: toward models and mechanisms. Semin. Cancer Biol. 1996, 7:291-298.
42. Silva A.J., et al. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat. Genet. 1997, 15:281-284.
43. Costa R.M., et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002, 415:526-530.
44. Guilding C., et al. Restored plasticity in a mouse model of neurofibromatosis type 1 via inhibition of hyperactive ERK and CREB. Eur. J. Neurosci. 2007, 25:99-105.
45. Ho I.S., et al. Distinct functional domains of neurofibromatosis type 1 regulate immediate versus long-term memory formation. J. Neurosci. 2007, 27:6852-6857.
46. Li W., et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 2005, 15:1961-1967.
47. Krab L.C., et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008, 300:287-294.
48. Cui Y., et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 2008, 135:549-560.
49. Brems H., et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat. Genet. 2007, 39:1120-1126.
50. Denayer E., et al. Observations on intelligence and behavior in 15 patients with Legius syndrome. Am. J. Med. Genet. C: Semin. Med. Genet. 2011, 157:123-128.
51. Pasmant E., et al. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J. Med. Genet. 2009, 46:425-430.
52. Wakioka T., et al. Spred is a Sprouty-related suppressor of Ras signalling. Nature 2001, 412:647-651.
53. Nonami A., et al. Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells. J. Biol. Chem. 2004, 279:52543-52551.
54. Denayer E., et al. Spred1 is required for synaptic plasticity and hippocampus-dependent learning. J. Neurosci. 2008, 28:14443-14449.
55. Aoki Y., et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat. Genet. 2005, 37:1038-1040.
56. Axelrad M.E., et al. Neurocognitive, adaptive, and behavioral functioning of individuals with Costello syndrome: a review. Am. J. Med. Genet. C: Semin. Med. Genet. 2011, 157:115-122.
57. Viosca J., et al. Germline expression of H-Ras(G12V) causes neurological deficits associated to Costello syndrome. Genes Brain Behav. 2009, 8:60-71.
58. Atkins C.M., et al. The MAPK cascade is required for mammalian associative learning. Nat. Neurosci. 1998, 1:602-609.
59. Giese K.P., et al. Hippocampus-dependent learning and memory is impaired in mice lacking the Ras-guanine-nucleotide releasing factor 1 (Ras-GRF1). Neuropharmacology 2001, 41:791-800.
60. Chen A.P., et al. Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory. J. Neurosci. Res. 2006, 83:28-38.
61. Lin C.H., et al. A role for the PI-3 kinase signaling pathway in fear conditioning and synaptic plasticity in the amygdala. Neuron 2001, 31:841-851.
62. Guo H.F., et al. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 2000, 403:895-898.
63. Buchanan M.E., Davis R.L. A distinct set of Drosophila brain neurons required for neurofibromatosis type 1-dependent learning and memory. J. Neurosci. 2010, 30:10135-10143.
64. Tully T., Quinn W.G. Classical conditioning and retention in normal and mutant Drosophila melanogaster. J. Comp. Physiol. A 1985, 157:263-277.
65. Margulies C., et al. Deconstructing memory in Drosophila. Curr. Biol. 2005, 15:R700-R713.
66. Williams J.A., et al. A circadian output in Drosophila mediated by neurofibromatosis-1 and Ras/MAPK. Science 2001, 293:2251-2256.
67. Rutten K., et al. Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice. Eur. J. Neurosci. 2008, 28:625-632.
68. Rutten K., et al. Sub-chronic rolipram treatment leads to a persistent improvement in long-term object memory in rats. Neurobiol. Learn. Mem. 2008, 90:569-575.
69. Li Y.F., et al. Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J. Neurosci. 2011, 31:172-183.
70. Rodefer J.S., et al. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. Neuropharmacology 2012, 62:1182-1190.
71. Wiescholleck V., Manahan-Vaughan D. PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis. Transl. Psychiatry 2012, 2:e89.
72. Hegedus B., et al. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell 2007, 1:443-457.
73. Brown J.A., et al. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J. Neurosci. 2010, 30:5579-5589.
74. Brown J.A., et al. Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner. Mol. Cell. Neurosci. 2012, 49:13-22.
75. Hegedus B., et al. Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma. J. Neuropathol. Exp. Neurol. 2009, 68:542-551.
76. Lin Y.L., et al. Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin-PKA-Ena/VASP pathway. J. Cell Biol. 2007, 177:829-841.
77. Wang H.F., et al. Valosin-containing protein and neurofibromin interact to regulate dendritic spine density. J. Clin. Invest. 2011, 121:4820-4837.
78. Volkow N.D., et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. 2001, 21:RC121.
79. Spencer T.J., et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am. J. Psychiatry 2006, 163:387-395.
80. Brown J.A., et al. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum. Mol. Genet. 2010, 19:4515-4528.
81. Brown J.A., et al. PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Exp. Neurol. 2011, 232:333-338.
82. Gasbarri A., et al. Spatial memory impairment induced by lesion of the mesohippocampal dopaminergic system in the rat. Neuroscience 1996, 74:1037-1044.
83. El-Ghundi M., et al. Spatial learning deficit in dopamine D(1) receptor knockout mice. Eur. J. Pharmacol. 1999, 383:95-106.
84. Xing B., et al. Dopamine D1 but not D3 receptor is critical for spatial learning and related signaling in the hippocampus. Neuroscience 2010, 169:1511-1519.
85. Diggs-Andrews K.A., et al. Dopamine deficiency underlies learning deficits in Neurofibromatosis-1 mice. Ann. Neurol. 2012, 10.1002/ana.23793.
86. Le L.Q., et al. Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. Cancer Res. 2011, 71:4686-4695.
87. Zhu Y., et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005, 8:119-130.
88. Bajenaru M.L., et al. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell. Biol. 2002, 22:5100-5113.
89. Lee D.Y., et al. Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. Cancer Cell 2012, 22:131-138.
90. Le L.Q., et al. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell 2009, 4:453-463.
91. Alcantara Llaguno S., et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009, 15:45-56.
92. Zhu Y., et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 2005, 132:5577-5588.
93. Bajenaru M.L., et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 2003, 63:8573-8577.
94. Zhu Y., et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002, 296:920-922.
95. Zhu Y., et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 2001, 15:859-876.
96. Lee D.Y., et al. Neurofibromatosis-1 regulates neuroglial cell progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev. 2010, 24:2317-2329.
97. Reilly K.M., et al. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat. Genet. 2000, 26:109-113.
98. Reilly K.M., et al. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:13008-13013.
99. Hawes J.J., et al. Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. Neurogenetics 2007, 8:121-130.
100. Daginakatte G.C., Gutmann D.H. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum. Mol. Genet. 2007, 16:1098-1112.
101. 2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res. 2008, 68:10358-10366.
102. Simmons G.W., et al. Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth. J. Neuropathol. Exp. Neurol. 2011, 70:51-62.
103. Yang X., et al. Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res. 2006, 16:995-1004.
104. McCarthy M.M., Arnold A.P. Reframing sexual differentiation of the brain. Nat. Neurosci. 2011, 14:677-683.
105. Brennan K.C., et al. Reduced threshold for cortical spreading depression in female mice. Ann. Neurol. 2007, 61:603-606.
106. Wang Y., et al. ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell 2012, 150:816-830.
107. Wong M., et al. Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Ann. Neurol. 2003, 54:251-256.
108. Zeng L.H., et al. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol. Dis. 2007, 28:184-196.
109. Bennett M.R., et al. Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants. J. Neurosci. 2003, 23:7207-7217.
110. Schafer D.P., et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012, 74:691-705.
111. Paolicelli R.C., et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011, 333:1456-1458.
112. Acosta M.T., et al. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatric Neurol. 2011, 45:241-245.
113. Strand M.T., et al. Improving working memory in children with attention-deficit/hyperactivity disorder: the separate and combined effects of incentives and stimulant medication. J. Abnorm. Child Psychol. 2012, 40:1193-1207.
114. Ferner R.E., et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 2007, 44:81-88.
115. Williams V.C., et al. Neurofibromatosis type 1 revisited. Pediatrics 2009, 123:124-133.